Introduction
HIV remains a significant global health problem. In 2020, an estimated 680 000 individuals died from HIV-related causes globally, while there were 1.5 million new infections.1 Although HIV-related mortality has declined nearly 50% over the past decade, declines in new infections have been sluggish, particularly among key populations at elevated risk of infection (eg, men who have sex with men, transgender people, people who inject drugs and adolescent girls and young women).1 To address the high burden of new infections among these populations, there exists a pressing need to rapidly expand access to high-quality HIV prevention programming.
The introduction of oral pre-exposure prophylaxis (PrEP) was a watershed moment in the history of HIV prevention. When taken on a daily or on-demand basis, PrEP use can substantially lower the likelihood of HIV acquisition.2 3 Yet despite PrEP’s immense promise, its global scale up has been slow.4 Like HIV treatment, high-quality PrEP services can be conceptualised according to a ‘cascade’ of necessary, sequential steps, extending from PrEP awareness and initiation through to PrEP adherence and retention.5 Persistence (ie, ongoing use) and adequate adherence to recommended dosing in the setting of HIV risk are key components of the PrEP cascade that, if not effectively promoted and supported, have the potential to undermine PrEP’s effectiveness.6 To be maximally protective, PrEP use must consistently coincide with potential HIV exposure events (ie, prevention-effective adherence),7 but data suggest that PrEP discontinuation is common, with many individuals discontinuing PrEP within the first 6 months of initiation.8 Although discontinuation of PrEP in the absence of anticipated HIV exposure may be ‘strategic, effective and efficient,’7 people who discontinue PrEP in the setting of ongoing exposure events and inconsistent or absent condom use during sexual intercourse may be at risk for HIV acquisition.9
Psychosocial factors are a central concern in PrEP discontinuation. Empirical data about predictors of PrEP persistence are scant, but a recent qualitative study of people recruited through San Francisco safety-net clinics who acquired HIV despite initiating PrEP implicated substance use and poor mental health as contributors to discontinuation.10 Mental disorders have long been shown to amplify the risk of HIV acquisition among men who have sex with men through diminished self-efficacy, increased compulsivity, and reduced engagement in HIV preventive behaviours.11 12 High rates of mental disorders have also been reported among other at-risk populations, including adolescent girls and young women in sub-Saharan Africa.13 Unfortunately, screening and treatment rates for these disorders remain low, particularly in low-income and middle-income countries (LMICs) with high burdens of HIV. Given the mutually causal link between mental disorders and HIV risk, an approach to PrEP scale up that focuses solely on HIV risk reduction without consideration of individuals’ mental health and psychosocial needs is untenable.4
In this analysis, we describe the burden of mental disorders among populations that are likely to benefit from PrEP. We review findings showing that mental disorders may undermine long-term persistence with PrEP and therefore warrant the attention of researchers and implementers seeking to maximise the effectiveness of PrEP at the population level. We conclude that the ambitious scale up of PrEP offers an opportunity to undertake concurrent scale up of screening and treatment for mental disorders, both as a strategy to improve PrEP effectiveness and as a pathway to expand access to mental healthcare among populations at elevated risk of HIV acquisition.